The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers.

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of severe RSV disease. ACIP had made the recommendation in a 14-0 vote, with ...

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu immunizations in 2025. The panel voted to expand RSV protection for ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention (CDC).

RSV-associated hospitalization rates cut by nearly half in infants aged 0 to 2 months after the rollout of the new vaccines. The CDC has also recorded a reduction of 31% to 38% in hospitalization ...

CDC advisors voted to lower the age of RSV vaccination to include people as young as age 50. In the absence of a director, the recommendation will be sent to the CDC chief of staff for consideration.

The mRNA-based RSV shot, mRESVIA, secured U.S. approval on Thursday for use in at-risk adults aged 18 to 59 years, but needs the U.S. Centers for Disease Control and Prevention's advertisement ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The… ...